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Background: The newest release of the Eclipse (Varian) treatment planning system (TPS) includes an optimizing
engine for Elekta volumetric-modulated arc therapy (VMAT) planning. The purpose of this study was to evaluate this
new algorithm and to compare it to intensity-modulated radiation therapy (IMRT) for various disease sites by
creating single- and double-arc VMAT plans.
Methods: A total of 162 plans were evaluated in this study, including 38 endometrial, 57 head and neck, 12 brain,
10 breast and 45 prostate cancer cases. The real-life IMRT plans were developed during routine clinical cases using
the TPS Eclipse. VMAT plans were generated using a preclinical version of Eclipse with tumor-region-specific
optimizing templates without interference of the operator: with one full arc (1A) and with two full arcs (2A), and
with partial arcs for breast and prostate with hip implant cases. All plans were evaluated based on target coverage,
homogeneity and conformity. The organs at risk (OARs) were analyzed according to plan objectives, such as the
mean and maximum doses. If one or more objectives were exceeded, the plan was considered clinically unacceptable,
and a second VMAT plan was created by adapting the optimization penalties once.
Results: Compared to IMRT, single- and double-arc VMAT plans showed comparable or better results concerning the
target coverage: the maximum dose in the target for 1A is the same as that for IMRT; for 2A, an average reduction of
1.3% over all plans was observed. The conformity showed a statistically significant improvement for both 1A (+3%) and
2A (+6%). The mean total body dose was statistically significant lower for the considered arc techniques (IMRT: 16.0 Gy,
VMAT: 15.3 Gy, p < 0.001). However, the sparing of OARs shows individual behavior that depends strongly on the
different tumor regions. A clear difference is found in the number of monitor units (MUs) per plan: VMAT shows a
reduction of 31%.
Conclusion: These findings demonstrate that based on optimizing templates with minimal interaction of the
operator, the Eclipse TPS is able to achieve a plan quality for the Elekta VMAT delivery technique that is comparable to
that of fixed-field IMRT. Plans with two arcs show better dose distributions than plans with one arc.
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Volumetric-modulated arc therapy (VMAT) is a com-
plex, arc-based treatment technique for intensity-
modulated radiation therapy (IMRT). Combining simul-
taneously varying dose rate, gantry speed and the shape
of the multileaf collimator (MLC) aperture, VMAT is
the obvious evolution of fixed-field IMRT and intensity-
modulated arc therapy (IMAT) delivery [1-9].
The VMAT technique has become clinically and com-
mercially available for bothVarian (Varian Medical Systems,
Palo Alto, CA, USA) and Elekta (Elekta AB, Stockholm,
Sweden) linear accelerators. Different treatment planning
systems (TPS) are available for accelerators from both man-
ufacturers, and the VMAT technique produces plan quality
and dose distributions that are comparable and often super-
ior to those of fixed-field step-and-shoot or sliding window
IMRT for a wide range of disease sites [10-20]. Moreover,
the essential advantage of the VMAT technique is the
improved efficiency of the treatment in terms of signifi-
cant reduction of the number of monitor units (MUs)
and the shorter delivery time [10,21,22].
VMAT planning for Elekta linear accelerators is
supported with the following commercial and clinical
routine treatment planning systems: SmartArc as a
part of pinnacle3 (Philips, Fitchburg WI, USA), Oncentra
Masterplan (Nucletron BV (Elekta), Veenendaal, The
Netherlands), RayStation (RaySearch Laboratories AB,
Stockholm, Sweden) and Monaco (Elekta). To date, it
has only been possible to create VMAT plans performed
in Eclipse (Varian) using the RapidArc® optimizing algo-
rithm, referred to as the progressive resolution optimizer
algorithm (PRO) based on the principle described by
Otto [1], for Varian linear accelerators [23]. The newest
release of the Eclipse TPS (v. 11.0.39) includes a slightly
modified PRO algorithm (129 control points instead of
180 for one full arc) for Elekta VMAT planning [24].
The purpose of this study was to evaluate this algo-
rithm for different disease sites by creating single- and
double-arc VMAT plans. Depending on the TPS, achiev-
ing acceptable plans is more or less strongly affected by
the operator’s experience level. To exclude this qualitative
and difficult-to-measure effect, a template based method
that allows plans to be generated with almost no user
interaction will be introduced. Therefore, the quality of
the optimizer can be analyzed. The dynamic arc plans
are compared to clinical step-and-shoot IMRT plans on
a statistical basis.
Materials and Methods
Patient plan selection and planning objectives
From five different tumor regions – head and neck,
brain, cervical and endometrial, breast and prostate –
162 fixed-field step-and-shoot IMRT plans that were
used for patient treatment between January 2009 andJune 2012 on an Elekta Synergy Linac were examined.
These patient plans included the following:
– 38 cervical and endometrial cancer cases with a
prescribed dose of 45 Gy to the planning target
volume (PTV) of the first series planned with 7 fields;
– 57 head and neck (HN) cancer cases with a
simultaneously integrated boost (SIB), of which 18
involved adjuvant radiotherapy with a prescribed
dose of 64 Gy for PTV1 with one additional dose
level (PTV2: 11 × 54 Gy; 7 × 56.1 Gy) planned with
7 fields; the remaining 39 involved definitive
radiotherapy with a prescribed dose of 69.3 Gy
(PTV1) with one (PTV2: 8 × 54 Gy and 7 × 56.1 Gy)
or two additional dose levels (PTV2: 24 × 56.1 Gy and
PTV3: 52.8 Gy), all planned with 7 fields;
– 12 brain cancer cases with a prescribed dose of
60 Gy (planned with 5 to 7 fields);
– 10 breast cancer cases with a prescribed dose of
50 Gy, including 6 left and 4 right sided irradiations
(planned with 6 to 8 fields);
– 45 prostate cancer cases, of which 18 involved one
hip implant and 16 involved two hip implants, both
with a prescribed dose of 74 Gy (planned with 5
fields); the remaining 11 cases involved pelvic
lymph nodes (LNs) included in the PTV with a
prescribed dose of 45 Gy for the first series
(planned with 7 fields).
We sought to achieve various planning objectives ac-
cording to our clinical protocols for PTV and organs at
risk (OARs). These values are listed in Table 1. Plans
were called “clinically acceptable” if all objectives were
met (“in tolerance”). The study was performed based on




All IMRT and VMAT plans were created using the same
6 MV photon beams commissioned for an Elekta Syn-
ergy Linac equipped with an MLCi multileaf collimator
(40 leaf pairs with 1 cm width, maximum leaf speed of
2.5 cm/s; no interdigitation), maximum gantry speed of
6°/s and variable dose rate up to 500 MU/s (seven fixed
dose rate levels were available, each of which was half
the dose rate of the next higher level without continuous
adjustment).
IMRT
The clinical step-and-shoot IMRT plans were generated
using the Eclipse treatment planning system (version 8.6,
Varian Medical Systems). Depending on the tumor
region, 5 to 9 coplanar fields were chosen, consistent
Table 1 Planning objectives for organs at risk and target
volumes





Optical nerveb 50 Gy
Lips 45 Gy
Parotid glands V28 Gy < 50%
Spinea 45 Gy
Lung V20 Gy < 20%; Dmean < 15 Gy
Lungs, both V5 Gy < 65%; V20 Gy < 20%;
Dmean < 13 Gy
Heart V30 Gy < 20%; Dmean < 15 Gy
Small intestine V45 Gy < 78 cm
3
Bladder V40 Gy < 55%; V60 Gy < 25%;
V70 Gy < 5%
Rectum V40 Gy < 60%; V60 Gy < 40%;
V70 Gy < 20%
PTV1 110%c V95% > 95%
PTV2 and PTV3
(sub-dose levels)
110%c V95% > 95%; D50% in
[98.5% - 101.5%]c
Note: PTV = planning target volume; V95% = volume of PTV receiving 95% of
prescription; D50% =median dose; Vn Gy = volume of structure receiving ≥ n Gy;
aobjectives are to be counted including an additional margin of 5 mm,
bobjectives are to be counted including an additional margin of 3 mm; cin
relation to the prescribed dose.
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process was started with standardized optimizing tem-
plates (predefined settings of penalty-functions using
dose-volume objectives with a certain weight) followed
by individual adaptations to achieve the clinical objec-
tives (Table 1). Depending on the tumor region at least
3 (prostate, cervical) to 6 (breast, head and neck, brain)
attempts were taken to get a clinically acceptable IMRT
plan. The dose calculation was performed using the
anisotropic analytic algorithm (AAA) [25] and a grid
size of 2.5 mm.
VMAT
VMAT plans were generated using a preclinical version
of the TPS Eclipse (v. 11.0.16). For all corresponding
IMRT plans, single-arc (1A) and double-arc plans (2A)
were created. Except for the prostate plans with hip im-
plants and breast irradiation, a 358° counter-clockwise
rotation for 1A with 129 control points was used;
double-arc plans corresponded to two 358° coplanar
arcs with the same isocenter in clockwise and counter-
clockwise directions. For breast cancer cases, partial
arcs of 240° (180° to 300° for left sided targets and 60° to
180° for right sided targets) were used to avoid entrancedoses to the contralateral lung. For cases with one hip
implant, two resp. four partial arcs were used to avoid
direct irradiation of the metal prosthesis; for cases with
two hip implants, three and six partial arcs were used.
The length of the arcs was adjusted separately for each
case (one implant: 60° and 275° on average; two im-
plants: left 55°, middle 76° and right 60°). In all cases,
the isocenter was placed in the center of the PTV. The
collimator angle was set to 30° for counter-clockwise
rotation and to 330° for clockwise rotation. The dose
calculation was performed with the AAA algorithm and
a grid size of 2.5 mm; for the optimization, the PRO3
algorithm was used.Optimizing procedure for VMAT
Based on the available IMRT optimizing templates, new
VMAT optimizing templates for each treatment region
and prescribed dose were created (in total 10 different
templates: cervical, HN 64 Gy/54 Gy, HN 64 Gy/56.1 Gy,
HN 69.3 Gy/54 Gy, HN 69.3 Gy/56 Gy, HN 69.3 Gy/56.1
Gy/52.8 Gy, breast, prostate LN, prostate 74 Gy, brain; a
description of the templates can be found in the Additional
file 1). All these templates were tested on a few patients
to evaluate whether they produced reasonable results
concerning the plan quality in comparison to IMRT
and concerning the irradiation by measuring the treat-
ment time and dose distribution [26]. Using these
templates for all corresponding IMRT plans, 1A and
2A plans were created. During the optimizing process,
the objectives or weights were not adjusted to exclude
the influence of the operator, which allows an objective
and independent evaluation of the dose distribution of
all tumor regions. After the optimizing process and the
final dose calculations, the dose distribution was evalu-
ated according the clinical planning objectives (Table 1)
and was compared against the original IMRT plan as a
benchmark. If one or more objectives were not met, a
second VMAT plan (1Am resp. 2Am) was created start-
ing with the same template. At the beginning of this
second optimizing process, the penalties (dose-volume
objective and/or weight) corresponding to the clinical
objectives out of tolerance were manually adapted based
on the experience of IMRT planning. The adapted plans
were then evaluated again and no further adapted plans
were created, even if any objectives were not met.Evaluation
Dose-volume histogram and evaluation parameters
To quantitatively compare the VMAT plans to the ori-
ginal IMRT plans, dose-volume histograms (DVHs) were
used. To visualize the differences, average cumulative
DVHs were calculated per examined tumor region for
each organ and treatment technique.
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maximum dose and partial volume values according to
the clinical objectives (Table 1) were derived from the
DVHs and average values for each treatment technique
and tumor region were calculated, where the average
values for 1Am and 2Am include the values of the non-
modified plans of the corresponding tumor region. For
the PTV beside maximum dose, V95% and values for the
homogeneity and conformity were evaluated; the homo-




where D5% and D95% are the minimum doses received by
5% and 95% of the PTV, respectively; 1 is the smallest
and ideal value. The conformity was calculated with the
conformation number (van’t Riet model) [27]:
CN ¼ TVRI ⋅ TVRI
TV ⋅ VRI
ð2Þ
where TVRI is the target volume covered by the refer-
ence isodose (95% of prescription), TV is the target
volume (PTV) and VRI is the volume of the reference
isodose. CN ranges from 0 to 1, where 1 is the ideal
value. For sub-dose levels (PTV2, PTV3), the median
dose D50% was evaluated. In addition to the above
mentioned metrics, the mean body dose, the volume of
the body receiving 5 Gy or more (V5 Gy) and the num-
ber of used MUs per fraction were estimated as a
measure for scatter dose.
Statistical analyses
The results of VMAT and IMRT plans were compared
to the two-sided Wilcoxon matched-pair signed-rank
test. The threshold for statistical significance was set at
p < 0.05; a p-value less than 0.01 is considered highly
significant. The DVH calculations and statisticalTable 2 Ratios of acceptable VMAT plans
Number Plan
Site of plans 1A 1Am 2A 2Am 1A
Brain 12 33% 42% 42% 50% 50%
Breast 10 50% 50% 90% 90% 50%
Endometrial 38 16% 24% 50% 61% 21%
HN 64 Gy 18 33% 44% 44% 56% 61%
HN 69.3 Gy 39 21% 28% 21% 36% 41%
Prostate 1 Impl. 18 44% 50% 61% 78% 50%
Prostate 2 Impl. 16 31% 44% 38% 69% 69%
Prostate LN 11 73% 91% 100% 100% 73%
Total 162 31% 40% 48% 60% 46%
Before (1A, 2A) and after modification (1Am, 2Am) of the optimization penalties div
middle, ratios for the PTV only; on the right, ratios for the OARs only.analyses were performed using MatLab (v 7.7.0.471
[R2008b], The MathWorks Inc., Natick, MA, USA).
Results
Clinically acceptable VMAT plans showing compar-
able dose distributions to IMRT plans were achieved
for all evaluated tumor regions: clinically acceptable
2A plans were achieved without interference of the
operator in 48% of all cases (ranging from 21% for HN
69.3 Gy to 100% for prostate with LN), and acceptable
1A plans were achieved in 31% of all cases (ranging
from 16% for endometrial to 73% for prostate with
LN). After modifying the optimization penalties of the
plans out of tolerance, 62% of the double-arc plans
were acceptable, and 41% of the single-arc plans were
acceptable. Considering the OARs only, acceptable
plans would be achieved in 57% to 75% of cases. For
PTV only, double-arc plans would be acceptable in
72% to 73% of cases, and single-arc plans in 46% of
cases for 1A and 49% of cases for 1Am. Between the
evaluated tumor regions and prescribed doses, differ-
ences were identified. The corresponding data are
listed in Table 2.
Table 3 summarizes the averaged results in terms of
PTV coverage, total body dose and number of MUs of all
162 cases. The mean total body dose was statistically
significant lower for all VMAT cases than for IMRT
(−0.7 Gy); however, the V5Gy was higher (+0.6%). The
number of monitor units was statistically significant lower
for VMAT by factors of 1.4 for double-arc and 1.5 for
single-arc plans. The PTV coverage for double-arc plans
was better than for IMRT (ΔDmax: −1.3%, ΔCN: +0.06,
ΔHI: −0.01); V95% revealed no difference. Single-arc plans
had clearly lower V95% values (1A: −1.8%, 1Am: −2.0%)
and worse homogeneity (+0.01) than IMRT.
In a comparison of single- and double-arc techniques,
the PTV coverage was significantly different for plans with
two arcs. However, double-arc plans had approximatelyPTV OAR
1Am 2A 2Am 1A 1Am 2A 2Am
50% 67% 58% 42% 42% 50% 50%
50% 90% 90% 100% 100% 100% 100%
26% 68% 68% 66% 66% 74% 82%
67% 94% 100% 44% 61% 50% 61%
44% 44% 49% 38% 46% 38% 59%
56% 78% 83% 61% 72% 72% 89%
63% 88% 81% 44% 63% 44% 81%
91% 100% 100% 100% 100% 100% 100%
49% 72% 73% 57% 64% 61% 75%
ided by tumor site: on the left, ratios for the total plans are shown; in the
Table 3 Comparison between IMRT and VMAT for all 162 evaluated patient plans
IMRT (n = 162) 1A (n = 162) 1Am (n = 162) 2A (n = 162) 2Am (n = 162)
PTV
Dmax (%) 108.9 (103.9 - 120.3) 108.8 (104.4 - 119.9)
b 109.1 (104.8 - 119.7)c 107.6 (103.6 - 115.2)ab 107.6 (103.6 - 116.0)ac
V95% (%) 94.2 (83.3 - 100.0) 92.4 (75.6 - 99.8)
ab 92.2 (81.8 - 99.6)ac 94.2 (75.6 - 99.9)b 94.3 (81.0 - 99.9)c
HI 1.10 (1.05 - 1.20) 1.11 (1.04 - 1.38)ab 1.11 (1.05 - 1.23)ac 1.09 (1.04 - 1.35)ab 1.09 (1.04 - 1.22)ac
CN 0.76 (0.22 - 0.91) 0.79 (0.26 - 0.93)ab 0.79 (0.30 - 0.93)ac 0.81 (0.29 - 0.94)ab 0.82 (0.40 - 0.94)ac
Body
Dmean (Gy) 16.0 (3.7 - 42.8) 15.2 (3.6 - 39.0)
a 15.2 (3.6 - 39.9)a 15.3 (3.6 - 39.2)a 15.3 (3.6 - 40.4)a
V5 Gy (%) 31.7 (6.6 - 70.6) 32.1 (6.8 - 69.8)
ab 32.2 (6.8 - 69.6)ac 32.4 (7.0 - 70.1)ab 32.4 (7.0 - 70.4)ac
MU 621.4 (307–1123) 406.9 (261–833)ab 424.4 (279–833)ac 435.1 (156–939)ab 442.2 (156–939)ac
Single and double arc plans before (1A, 2A) and after modification (1Am, 2Am) of the optimization penalties; values are expressed as the mean (range).
ap < 0.01 for Wilcoxon matched-pair signed rank test vs. IMRT; bp < 0.01 1A vs. 2A; cp < 0.01 1Am vs. 2Am.
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to 1Am and 2A to 2Am were not significant, and slight
declines were identified for single-arc plans in both max-
imum dose and V95%.
Cervical and endometrial cases
Of the 38 cervical and endometrial cases for the double-
arc technique, 19 were in tolerance for both OAR spar-
ing and PTV coverage; after adapting the optimization
penalties, 23 plans met all objectives. For the single-arc
technique (1A), six plans were acceptable after adapting
(1Am) nine. For most non-acceptable plans, the follow-
ing values were out of tolerance: Dmax of the PTV (1A:
10 plans, 2A: 5), V95% (1A: 30 plans, 2A: 10) and V40 Gy
of the bladder (1A and 2A: 7 plans).
In Table 4, the averaged results in terms of PTV cover-
age, OAR doses and number of MUs are summarized.
The doses in the OARs were similar to IMRT for both
single- and double-arc plans; small but significant differ-
ences were detected for total body dose (Dmean: −0.8 Gy;
V5 Gy: +1.5% for 2A) and Dmax of the bladder (−0.9 Gy
for 2A). Double-arc plans showed a significant reduction of
high-dose regions in the small intestine (V45 Gy: −4.7 cm
3),
but the mean dose was higher for VMAT (+1.2 Gy). The
PTV coverage had highly significant lower V95% values for
all arc techniques (IMRT 96.2%, 1A: 92.6%, 2A: 95.2%).
The maximum target dose and the conformity were better
for double-arc plans than for IMRT; for single-arc plans,
the corresponding values were below the mean values of
IMRT. The number of MUs for VMAT was statistically
significant lower than for IMRT, with reductions ranging
from 34% for 2Am to 43% for 1A. Comparing single- and
double-arc plans, all parameters (except MUs) exhibited
differences in favor of the double-arc technique, and
differences in the parameters for PTV coverage, max-
imum dose in the bladder and rectum were statistically
significant. The averaged DVH comparison is plotted
in Figure 1.Head and neck cases
Of the 18 adjuvant cases with prescriptions of 64 Gy, for
the double-arc technique, 8 plans met the clinical objec-
tives, 10 after modifications. For the single-arc tech-
nique, 6 plans met the clinical objectives, 8 plans after
modifications. Cases with target doses of 69.3 Gy for
definitive radiation therapy had acceptable 2A plans in 8
cases out of 39; after adapting the optimization penalties,
the number of acceptable plans was increased to 14;
eight single-arc plans were acceptable, 11 after modifica-
tion. In all non-acceptable plans, either V95% of the
PTV1 was too small (1A: 25 plans, 2A: 22) or the object-
ive for V28 Gy in one of the parotid glands was exceeded
(1A: 25 plans, 2A: 24); the other values out of tolerance
were Dmax for brainstem (1A: 11 plans, 2A: 5) and spine
(1A and 2A: 12 plans).
Table 5 lists the detailed results for the head and neck
cases with prescriptions of 69.3 Gy. Significant differ-
ences in IMRT for single- and double-arc plans were
noted for total body dose (Dmax: −0.4 Gy; V5 Gy: +0.3%).
The maximum doses to the lips and the brain exhibited
no clear differences between IMRT and VMAT. Dmax in
the brain stem was significantly higher with the VMAT
plans (IMRT: 39.3 Gy; 1Am: 42.9 Gy; 2A: 43.1 Gy).
However, the maximum spine dose was clearly lower for
all VMAT techniques (up to −2.3 Gy). The mean dose
and V28 Gy for the parotid glands were slightly better for
VMAT after modification of the optimizing process;
before modification, they were significantly better for
IMRT. The dose coverages in the PTV2 and PTV3 were
generally better for VMAT than for IMRT. However,
V95% after modification was worse than before modifica-
tion, particularly for 1Am of 56.1 Gy, where IMRT was
significantly better (+5.5%). The median dose of the
sub-dose levels was significantly higher than in IMRT
(−1.9%); however, after modification, no clear differences
were identified. In the 69.3 Gy-target volume, the max-
imum dose was statistically significant lower (up to −0.8%)
Table 4 Comparison between IMRT and VMAT for 38 cervical and endometrial plans
IMRT (n = 38) 1A (n = 38) 1Am (n = 38) 2A (n = 38) 2Am (n = 38)
PTV
Dmax (%) 109.9 (106.7 - 113.5) 110.2 (107.4 - 117.3)
b+ 111.3 (107.4- 117.3)ac+ 109.3 (106.2 - 115.2)ab+ 109.4 (106.2 - 113.0)c+
V95% (%) 96.2 (89.5 - 98.7) 92.6 (86.8 - 96.3)
a+b+ 91.9 (83.2 - 96.3)a+c+ 95.2 (90.6 - 98.4)a+b+ 95.2 (89.4 - 98.4)a+c+
HI 1.09 (1.07 - 1.13) 1.11 (1.09 - 1.16)a+b+ 1.12 (1.09 - 1.18)a+c+ 1.09 (1.07 - 1.13)b+ 1.09 (1.07 - 1.14)c+
CN 0.77 (0.65 - 0.89) 0.79 (0.65 - 0.86)b+ 0.77 (0.62 - 0.85)c+ 0.83 (0.71 - 0.89)a+b+ 0.83 (0.68 - 0.89)a+c+
Body
Dmean (Gy) 13.8 (9.1 - 19.3) 13.1 (8.3 - 17.5)
a+ 13.2 (8.3 - 17.9)a+c 13.0 (8.3 - 17.6)a+b 13.1 (8.3 - 18.2)a+c
V 5Gy (%) 54.6 (37.4 - 70.6) 55.9 (39.1 - 69.8)
a+b 56.1 (39.2 - 69.6)a+ 56.1 (39.5 - 70.1)a+ 56.1 (39.5 - 70.4)a+
Rectum
V40 Gy (%) 42.3 (0.1 - 100.0) 43.9 (0.9 - 100.0) 43.7 (0.1 - 100.0) 44.0 (0.3 - 100.0) 43.3 (0.7 - 100.0)
Dmax (Gy) 46.9 (41.1 - 49.6) 47.2 (43.8 - 48.8)
b+ 47.2 (42.2 - 49.3)c+ 46.8 (41.7 - 48.1)b+ 46.8 (42.0 - 48.7)c+
Bladder
V40 Gy (%) 44.7 (7.4 - 100.0) 44.2 (8.6 - 100.0) 43.7 (8.4 - 99.6) 43.8 (6.5 - 100.0) 43.5 (9.4 - 100.0)
Dmax (Gy) 48.2 (46.3 - 49.6) 47.8 (46.3 - 49.4)
a+b+ 48.1 (46.3 - 50.6)c+ 47.3 (44.1 - 48.9)a+b+ 47.4 (44.4 - 49.8)a+c+
Small Intestine
V45 Gy (ccm) 29.3 (0.0 - 182.8) 30.2 (0.0 - 161.8) 32.7 (0.1 - 185.5) 24.0 (0.0 - 161.4)
a+ 25.3 (0.0 - 155.7)a+
Dmean (Gy) 26.8 (10.9 - 36.4) 28.0 (11.3 - 40.6) 28.0 (11.3 - 38.6) 27.9 (11.0 - 39.4)
a 28.0 (11.0 - 39.5)a+
MU 701.7 (496–850) 399.7 (324–515)a+b+ 457.6 (322–641)a+ 436.6 (356–590)a+b+ 460.6 (363–621)a+
Single and double arc plans before (1A, 2A) and after modification (1Am, 2Am) of the optimization penalties; values are expressed as the mean (range).
ap < 0.05 for Wilcoxon matched-pair signed rank test vs. IMRT; bp < 0.05 1A vs. 2A; cp < 0.05 1Am vs. 2Am; +p < 0.01.
























Figure 1 Mean DVHs of 38 cervical and endometrial cases. Solid line: IMRT; thin dashed line: 1A; thin dotted line: 2A; fat dashed line: 1Am;
fat dotted line: 2Am.
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Table 5 Comparison between IMRT and VMAT for 39 head and neck plans with a prescription of 69.3 Gy
IMRT (n = 38) 1A (n = 38) 1Am (n = 38) 2A (n = 38) 2Am (n = 38)
PTV 69.3Gy
Dmax (%) 107.6 (103.9 - 110.3) 107.9 (104.4 - 112.7)
b+ 108.0 (105.7-111.8)ac+ 106.8 (104.4- 109.2)a+b+ 107.0 (104.4 - 109.9)c+
V95% (%) 93.4 (88.1 - 97.8) 91.5 (85.3 - 99.1)
a+ 91.0 (82.9 - 98.1)a+c 91.9 (86.1 - 99.1)a+ 91.6 (85.4 - 98.8)a+c
HI 1.10 (1.07 - 1.14) 1.11 (1.06 - 1.15)a+b+ 1.12 (1.07 - 1.17)a+c+ 1.10 (1.06 - 1.14)b+ 1.11 (1.06 - 1.14)c+
CN 0.77 (0.22 - 0.91) 0.81 (0.26 - 0.91)a+b+ 0.83 (0.30 - 0.92)a+c+ 0.84 (0.29 - 0.93)a+b+ 0.85 (0.40 - 0.93)a+c+
PTV 56.1Gy
Dmax (%) 127.8 (124.0 - 135.1) 122.7 (115.6 - 130.4)
a+ 123.2 (116.7-129.0)a+c+ 122.3 (117.0 - 126.4)a+ 122.1 (118.2-127.2)a+c+
V95% (%) 93.1 (81.7 - 97.9) 93.3 (85.5 - 97.3)
b+ 87.6 (80.3 - 94.9)a+c+ 96.1 (92.2 - 99.1)a+b+ 92.0 (84.1 - 97.2)c+
HI 1.21 (1.12 - 1.31) 1.19 (1.14 - 1.24)ab+ 1.21 (1.14 - 1.28)c+ 1.16 (1.10 - 1.22)a+b+ 1.18 (1.10 - 1.25)a+c+
CN 0.67 (0.46 - 0.82) 0.69 (0.42 - 0.83)b+ 0.69 (0.49 - 0.81)c+ 0.71 (0.44 - 0.85)a+b+ 0.73 (0.50 - 0.85)a+c+
D50% (%) 101.2 (99.0 - 104.3) 102.6 (101.1-105.9)
a+b+ 100.8 (99.5 - 102.1) 102.2 (101.0 -104.6)a+b+ 100.6 (98.9 - 101.9)a
PTV 54Gy
Dmax (%) 129.9 (106.5 - 136.3) 126.8 (114.5 - 134.6)
ab+ 126.8 (112.5 - 133.0)a 124.5 (110.7 -129.8)a+b+ 125.6 (109.1 - 132.9)a+
V95% (%) 90.1 (85.0 - 95.3) 94.0 (90.8 - 97.5)
a+b+ 89.0 (79.2 - 92.9) 96.1 (92.5 - 98.7)a+b+ 92.5 (87.3 - 97.5)
HI 1.22 (1.09 - 1.28) 1.20 (1.12 - 1.25)b+ 1.21 (1.12 - 1.31)c+ 1.17 (1.09 - 1.24)a+b+ 1.19 (1.09 - 1.27)a+c+
CN 0.70 (0.57 - 0.79) 0.73 (0.63 - 0.87)a+b+ 0.74 (0.65 - 0.81)a+ 0.76 (0.66 - 0.88)a+b+ 0.76 (0.65 - 0.87)a+
D50% (%) 100.1 (98.4 - 101.5) 102.4 (101.3-103.4)
a+b+ 100.6 (98.9 - 102.2) 101.9 (101.1- 103.2)a+b+ 100.5 (99.8 - 101.8)
PTV 52.8Gy
Dmax (%) 114.0 (103.9 - 134.7) 114.9 (109.6 - 128.2)
b+ 112.9 (108.0 - 126.5) 113.1 (109.1 - 127.3)b+ 112.0 (106.2 - 128.3)
V95% (%) 92.7 (73.0 - 99.5) 96.5 (91.7 - 99.3)
ab+ 91.9 (83.8 - 97.9)c+ 97.9 (95.5 - 99.8)a+b+ 95.1 (87.1 - 99.2)c+
HI 1.11 (1.07 - 1.21) 1.13 (1.09 - 1.18)b+ 1.13 (1.09 - 1.18)c+ 1.10 (1.07 - 1.14)b+ 1.11 (1.07 - 1.15)c+
CN 0.64 (0.47 - 0.75) 0.71 (0.63 - 0.84)a+ 0.72 (0.64 - 0.87)a+c 0.72 (0.64 - 0.84)a+ 0.74 (0.63 - 0.88)a+c
D50% (%) 99.9 (98.0 - 102.7) 102.7 (101.5-104.5)
a+b+ 100.5 (99.5 - 101.5) 102.2 (101.0 -103.6)a+b+ 100.5 (99.1 - 101.8)
Body
Dmean (Gy) 7.1 (3.9 - 18.2) 6.7 (3.7 - 17.0)
a+ 6.6 (3.6 - 16.8)a+c+ 6.7 (3.7 - 17.0)a+ 6.6 (3.6 - 16.6)a+c+
V5Gy (%) 21.2 (10.6 - 56.6) 21.4 (10.7 - 58.2)
a+b+ 21.4 (10.7 - 57.5)a+c+ 21.6 (10.7 - 58.5)a+b+ 21.5 (10.8 - 58.7)a+c+
Brain
Dmax (Gy) 38.8 (3.7 - 62.9) 41.5 (5.2 - 60.4)
ab 40.1 (5.1 - 58.6) 40.1 (5.2 - 63.3)b 39.9 (5.0 - 60.7)
Brain stem
Dmax (Gy) 39.3 (20.6 - 51.0) 44.6 (22.2 - 51.5)
a+ 42.9 (18.9 - 52.5)a 44.3 (15.0 - 51.6)a+ 43.1 (17.0 - 51.0)a
Lips
Dmax (Gy) 28.6 (2.1 - 71.4) 29.1 (2.4 - 70.4) 28.3 (2.2 - 64.7) 30.4 (2.2 - 70.3) 29.8 (2.2 - 69.3)
Parotid gland
Dmean (Gy) 30.2 (7.8 - 62.7) 30.7 (9.7 - 55.7)
a+b+ 29.5 (9.7 - 55.8) 30.3 (9.6 - 55.7)ab+ 29.2 (9.8 - 56.0)
V28Gy (%) 48.1 (8.7 - 100.0) 49.6 (11.0 - 92.9)
a+b+ 46.6 (12.1 - 93.0) 48.2 (10.3 - 93.2)ab+ 45.6 (10.4 - 93.3)
Spine
Dmax (Gy) 37.4 (33.1 - 44.3) 36.3 (33.2 - 44.6)
ab+ 36.1 (32.7 - 44.0)ac+ 35.1 (32.5 - 41.0)a+b+ 35.3 (32.6 - 42.8)a+c+
MU 649.2 (458–802) 370.5 (313–524)a+b+ 372.9 (326–482)a+c+ 393.1 (322–558)a+b+ 393.6 (320–538)a+c+
Single and double arc plans before (1A, 2A) and after modification (1Am, 2Am) of the optimization penalties; values are expressed as the mean (range).
ap < 0.05 for Wilcoxon matched-pair signed rank test vs. IMRT; bp < 0.05 1A vs. 2A; cp < 0.05 1Am vs. 2Am; +p < 0.01.
Peters et al. Radiation Oncology 2014, 9:153 Page 7 of 15
http://www.ro-journal.com/content/9/1/153for double-arc plans than for IMRT, and the conformity
was clearly better for all VMAT techniques (up to +0.08).
However, V95% (up to −2.4%) and HI (+0.01) of the VMAT
plans were statistically significant below the IMRT
values. Comparing the single-arc and double-arc techniquesrevealed significant differences in favor of double-arc
plans concerning target coverage of PTV1 (Dmax: −1.0%,
V95%: −0.6%, HI: −0.01, CN: +0.02) and the sparing of
the spine (Dmax: −0.8 Gy). The averaged DVH compari-
son of all 39 plans is plotted in Figure 2.




























Figure 2 Mean DVHs of 39 head and neck cancer cases with prescriptions of 69.3 Gy. Solid line: IMRT; thin dashed line: 1A; thin dotted
line: 2A; fat dashed line: 1Am; fat dotted line: 2Am.
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http://www.ro-journal.com/content/9/1/153The averaged results for head and neck cases with tar-
get doses of 64 Gy were as follows. The mean total body
dose was similar for IMRT and VMAT; however, the
V5Gy value was lower for IMRT (−0.6%) than for double-
arc plans. The maximum doses in the brain and the
spine and the mean dose of the parotid glands showed
no difference between IMRT and VMAT. The maximum
dose in the lips was statistically significant lower for
VMAT (up to −6.0 Gy); however, the dose sparing in the
brain stem was better for IMRT (IMRT: 35.3 Gy; 1A:
42.7 Gy; 2A: 40.5 Gy). The dose coverage in the target
volumes was better for all VMAT techniques. Significant
differences were noted for the maximum doses for both
dose levels (PTV1 > 1.5%, PTV2 > 3.9%), for V95% (PTV1
for 2Arcs: 4.2%, PTV2: 4.4% (1A) and 6% (2A)) and for
CN of PTV1 (1A: 0.08, 2A: 0.12). Comparing the single-
and double arc techniques reveals significant differences
in favor of double-arc plans concerning target coverage of
PTV1 (Dmax: −0.9%, V95%: +2.3%, HI: −0.02, CN: +0.04),
sparing of the brain (Dmax: −1.8 Gy) and the brain stem
(Dmax: −1.4 Gy). Detailed values and the averaged DVH
comparison are shown in the Additional file 2.
Breast cases
An acceptable plan was achieved for the double-arc
technique in 9 out of 10 breast cancer cases; an acceptableplan was achieved in 5 cases for the single-arc technique.
In all non-acceptable cases (before and after adapting
the optimizing process), either the maximum target
dose was too high (1A: 2 plans, 1Am: 3) or the V95% was
too small (1A: 5 plans; 1Am: 3 plans; 2A and 2Am: 1
plan). The OARs met the clinical objectives in all cases
for all techniques.
For both single- and double-arc plans, the OARs and
total body dose showed slight but non-significant im-
provements compared to IMRT; however, the maximum
spine dose (1A: +1.9 Gy, 2A: +1.1 Gy, p > 0.05) and spar-
ing the contralateral lung with two arcs (V5 Gy: +2.1%,
Dmean: +0.2 Gy, p > 0.05) were better for IMRT. Signi-
ficant differences in IMRT in favor of VMAT were
only noted in the ipsilateral lung for double-arc plans
(V5 Gy: −7.5%, V20 Gy: −2.5%, Dmean: −2 Gy). The mean
dose for the heart seems to show a statistically signifi-
cant improvement for single arc plans (IMRT: 15.9 Gy,
1A 12.6 Gy, 1Am 12.8 Gy, p: 0.039). But the differences
depend on the side of the irradiated breast: for left-sided
breast irradiation, VMAT showed a slight improvement
(IMRT: 18.5 Gy, 1A: 12.7 Gy, 1Am: 12.8 Gy), whereas for
right-sided breast irradiation, no differences were noted
(IMRT: 12.6 Gy, 2A: 13.0 Gy, 2Am: 12.9 Gy). Due to the
low number of cases (6 left, 4 right), no statistical signifi-
cance for the differences can be given. VMAT plans with
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IMRT (Dmax: −7.5%; V95%: +2.7%; HI: −0.03; CN: +0.06),
while single-arc plans showed no clear difference compared
to IMRT (except for Dmax: −3.3% for 1A). A comparison of
single- and double-arc techniques revealed significant
differences in favor of double-arc plans concerning
target coverage (Dmax: −4.7%, V95%: −4.0%, HI: −0.04),
whereas there were no differences in terms of OAR
sparing. Detailed values and the averaged DVH com-
parison are shown in the Additional file 3.
Prostate cases
A total of 45 prostate cases were analyzed, of which 11
involved pelvic lymph nodes, 16 involved one hip im-
plant and 18 involved two hip implants. All 2A plans for
the LN cases met the clinical objectives; 1A plans were
acceptable in 8 cases, 10 after modification. Double-arc
plans with one implant were acceptable in 11 of the 18
total cases and in 14 cases after adapting the optimization
penalties. For the single-arc technique, 8 plans met the
objectives, 9 after modification. Cases with two implants
had acceptable 2A plans in 6 of 16 cases. After modify-
ing the optimization penalties, the number of acceptableTable 6 Comparison between IMRT and VMAT for 18 prostate
IMRT (n = 18) 1A (n = 18)
PTV
Dmax (%) 106.6 (104.2 - 112.5) 108.8 (104.9 - 115.4)
ab+ 109
V95% (%) 96.3 (89.2 - 100.0) 94.6 (85.4 - 99.6) 93
HI 1.09 (1.05 - 1.15) 1.10 (1.05 - 1.20)b+ 1.1
CN 0.78 (0.63 - 0.86) 0.71 (0.46 - 0.82)a 0.
Body
Dmean (Gy) 5.3 (3.9 - 9.0) 4.7 (3.4 - 7.2)
a+ 4
V5 Gy (%) 17.7 (11.4 - 29.1) 15.8 (10.3 - 23.4)
a 15
Rectum
V40 Gy (%) 57.0 (38.9 - 70.1) 62.2 (55.9 - 76.5)
a+ 61
V60 Gy (%) 28.1 (18.8 - 42.3) 35.8 (14.7 - 53.7)
a+ 34
V70 Gy (%) 4.2 (0.0 - 12.7) 6.6 (0.0 - 24.4) 5
Dmax (Gy) 72.5 (66.7 - 77.7) 73.5 (68.8 - 78.3) 7
Bladder
V40 Gy (%) 37.2 (20.5 - 76.5) 37.9 (23.0 - 68.1) 3
V60 Gy (%) 19.1 (9.3 - 38.2) 20.0 (10.3 - 38.9) 1
V70 Gy (%) 6.1 (0.0 - 21.3) 6.5 (0.0 - 25.5)
Dmax (Gy) 73.9 (67.4 - 79.9) 75.6 (69.0 - 83.7)
a+ 75
Implants
Dmax (Gy) 25.6 (4.3 - 74.4) 13.2 (3.5 - 66.7)
a+ 13
Dmean (Gy) 3.2 (0.9 - 8.1) 1.9 (0.7 - 6.0)
a+ 1
MU 585.3 (435–761) 488.1 (436–595)ab 49
Single and double arc plans before (1A, 2A) and after modification (1Am, 2Am) of t
ap < 0.05 for Wilcoxon matched-pair signed rank test vs. IMRT; bp < 0.05 1A vs. 2A; cplans increased to 11; 5 single-arc plans were accept-
able, 7 after modification.
For prostate cases with LNs, the sparing of the OARs
for both single- and double-arc plans were not different
compared to IMRT; however, in VMAT plans, the max-
imum dose in the rectum was smaller (1A: −1.0 Gy,
1Am: −0.8 Gy, 2A: −0.8 Gy). The mean total body dose
for VMAT was statistically significant lower than for
IMRT (−0.5 Gy), but in VMAT plans, the volume receiv-
ing 5 Gy was larger (up to +2.8%). The target coverage
was significantly better for double-arc VMAT than for
IMRT (Dmax: −3.5%; V95%: −1.9%, HI: −0.02, CN: +0.10).
Single-arc plans had smaller improvements in compari-
son to IMRT, with significant differences only for Dmax
(−2.0%) and conformity (+0.06). A comparison of single-
and double-arc plans revealed highly significant differ-
ences in favor of 2A in target coverage and the maximum
bladder dose. The Additional file 4 shows detailed results
and the averaged DVH comparison.
Prostate cases with one hip implant presented varying
results depending on the treatment technique. The blad-
der dose for VMAT plans was improved in comparison
to IMRT, where V60 Gy was statistically significant lowercases with two hip implants
1Am (n = 18) 2A (n = 18) 2Am (n = 18)
.1 (105.5 - 119.7)ac 107.6 (104.9 - 113.4)b+ 108.1 (104.9 - 116.0)c
.9 (82.7 - 99.6)a 96.2 (86.5 - 99.8) 95.6 (84.3 - 99.8)
1 (1.05 - 1.23)c+ 1.09 (1.04 - 1.19)b+ 1.09 (1.04 - 1.22)c+
72 (0.44 - 0.82)a 0.71 (0.46 - 0.81)a 0.71 (0.45 - 0.81)a
.7 (3.4 - 7.0)a+ 4.7 (3.4 - 7.2)a+ 4.7 (3.4 - 7.1)a+
.8 (10.3 - 21.9)a 15.8 (10.3 - 23.2)a 15.7 (10.2 - 22.4)a
.5 (55.9 - 72.7)a 62.5 (57.4 - 78.9)a+ 61.9 (57.4 - 75.8)a
.2 (13.9 - 51.5)a+ 36.2 (21.2 - 56.4)a+ 36.0 (21.2 - 54.8)a+
.7 (0.0 - 19.8)c 7.0 (0.0 - 25.5)a+ 6.3 (0.0 - 21.3)a+c
3.4 (68.0 - 78.4) 73.3 (68.1 - 77.5) 73.4 (68.2 - 77.5)
7.1 (23.0 - 63.9) 37.5 (24.2 - 63.1) 37.9 (24.2 - 69.7)
9.2 (10.9 - 40.7) 20.4 (11.7 - 40.4) 20.3 (10.3 - 40.3)
6.0 (0.0 - 27.5) 7.0 (0.0 - 27.8) 6.5 (0.0 - 28.2)
.4 (69.9 - 83.8)a 75.0 (69.5 - 81.9)a 74.9 (68.1 - 81.5)a+
.3 (3.6 - 67.4)a+ 13.3 (3.3 - 67.7)a+ 13.4 (3.5 - 66.7)a+
.9 (0.7 - 6.0)a+ 1.9 (0.7 - 6.6)a+ 1.9 (0.7 - 6.6)a+
1.4 (424–595)ac+ 536.0 (410–701)b 556.1 (415–744)c+
he optimization penalties; values are expressed as the mean (range).
p < 0.05 1Am vs. 2Am; +p < 0.01.
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http://www.ro-journal.com/content/9/1/153(−2.8%); the rectum dose was worse, as the maximum
dose (up to +1.3 Gy) and V40 Gy (up to +6.6%) were signifi-
cantly different. The mean dose in the femoral head was
statistically significant lower for IMRT in comparison to
both VMAT techniques (+3.6 Gy), but the sparing of the
implant was clearly better for VMAT (Dmax: −6.7 Gy,
Dmean: −0.7 Gy). Single-arc plans had significantly worse
target coverage than IMRT (Dmax +1.8G%, V95%: −2.0%,
HI: +0.01); double-arc plans were slightly worse than
IMRT but were not significantly different. However, con-
formity was significantly better for single- and double-arc
plans (CN: +0.07). Here, we identified the only cases in
which VMAT had more MUs than IMRT; however, the
differences (16 MUs on average) were not significant.
The differences between single- and double-arc plans
were small: significant differences in favor of 2A were
identified for target coverage (Dmax -0.9 Gy, V95%: −1.6%,
HI: −0.01; CN: +0.01). The total body and rectum doses
were better in favor of single-arc plans. Detailed values
and the averaged DVH comparison are shown in the
Additional file 5.
Table 6 lists the averaged values for OAR doses, target
coverage and the number of MUs for prostate cases with
two hip implants. The sparing of the OARs for both
single- and double-arc plans was slightly worse com-
























Figure 3 Mean DVHs of 18 prostate cancer cases with two hip implan
line: 1Am; fat dotted line: 2Am.(up to +8.1%) for the rectum and the Dmax of the bladder
(up to +1.7 Gy) were significantly different. However,
the sparing of the implants and the total body dose
were significantly reduced in comparison to the IMRT
plans (implant: Dmax: −12.3 Gy, Dmean: −1.3 Gy; body:
Dmean: −0.6 Gy; V5 Gy: −1.9%). The target coverage for
VMAT was worse than for IMRT, where single-arc plans
were significantly different in Dmax (up to +2.5%). The con-
formity was clearly better for the IMRT plans (CN: +0.07).
The number of MUs was statistically significant lower
for single-arc plans than for IMRT by a factor of 1.2; the
double-arc plans had slightly less MUs than IMRT
(−7%). The differences between single- and double-arc
plans were small; significant differences in favor of 2A
were noted for the maximum dose in the PTV (−1.2%)
and for the homogeneity (−0.01). The averaged DVH
comparison between the considered techniques is plot-
ted in Figure 3.
Brain cases
Of the 12 brain cancer cases, five 2A plans were ac-
ceptable for both OAR sparing and target coverage;
after adapting the optimization penalties, 6 plans met
all objectives. For single-arc technique, 4 plans were
accepted, 5 after adaptation. In the non-acceptable plans,




ts. Solid line: IMRT; thin dashed line: 1A; thin dotted line: 2A; fat dashed
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http://www.ro-journal.com/content/9/1/1535; 2A and 2Am: 4 plans) or the lens dose exceeded the
tolerance (1A: 6 plans; 1Am: 5 plans; 2A: 6 plans, 2Am:
5 plans).
Table 7 summarizes the average values for OAR
doses, target coverage and number of MU. The Dmax
of the brain stem was higher for VMAT than for IMRT
(up to +3.5 Gy); similar findings were obtained for the
chiasm (up to +1.8 Gy). However, the maximum doses of
the lenses and the optical nerves were lower for VMAT
(lenses: up to −1.8 Gy; opt. nerve: up to −3.4 Gy); after
modification, the Dmax of the right lens changed from
5.8 Gy to 9.0 Gy (IMRT: 10.5 Gy). For the right optical
nerve, increases of 2.0 Gy to 40.8 Gy for 2Am and 0.8 Gy
to 39.8 Gy for 1Am (IMRT: 42.3 Gy) were observed.
The maximum dose in the PTV and the conformity
were slightly better for VMAT; however, the homo-
geneity and V95% were better for IMRT. Significant
differences were only observed for conformity in both
modified single- and double-arc plans (CN: +0.06).
Differences between the two VMAT techniques wereTable 7 Comparisons between IMRT and VMAT for 12 brain c
IMRT (n = 12) 1A (n = 12)
PTV
Dmax (%) 108.1 (104.3 - 113.0) 107.8 (104.8 - 115.5) 107
V95% (%) 95.3 (90.6 - 99.3) 91.0 (75.6 - 99.2) 9
HI 1.09 (1.05 - 1.13) 1.14 (1.05 - 1.38) 1.
CN 0.78 (0.72 - 0.86) 0.80 (0.57 - 0.93) 0.8
Body
Dmean (Gy) 13.5 (3.8 - 21.9) 13.2 (4.4 - 21.0) 1
V5Gy (%) 43.2 (17.7 - 62.1) 45.3 (20.8 - 63.7)
a+ 45
Brain stem
Dmax (Gy) 50.0 (43.5 - 56.6) 53.1 (51.4 - 56.7)
a 53
Lenses
Dmax (Gy) 7.3 (1.0 - 49.3) 5.5 (1.5 - 11.8) 7
Lens lft
Dmax (Gy) 4.2 (1.2 - 11.9) 5.4 (1.5 - 11.8)
a+ 4
Lens rt
Dmax (Gy) 10.5 (1.0 - 49.3) 5.7 (1.5 - 11.1)
Chiasm
Dmax (Gy) 50.1 (43.2 - 56.7) 50.9 (32.7 - 60.7)
b 5
Optical nerves
Dmax (Gy) 43.2 (25.8 - 64.4) 40.2 (18.5 - 54.1) 4
Optical nerve lft
Dmax (Gy) 42.3 (27.3 - 52.6) 41.4 (29.3 - 50.4) 4
Optical nerve rt
Dmax (Gy) 44.1 (25.8 - 64.4) 39.0 (18.5 - 54.1) 3
MU 454.0 (330–775) 303.0 (261–342)a+ 3
Single and double arc plans before (1A, 2A) and after modification (1Am, 2Am) of t
ap < 0.05 for Wilcoxon matched-pair signed rank test vs. IMRT; bp < 0.05 1A vs. 2A; csmall and could be observed mainly in the PTV after
modification (Dmax: −0.9%, HI: −0.01, CN: +0.01) and in
the total body dose (Dmean -0.1 Gy, V5 Gy: 0.2%). The DVH
comparison of these techniques is plotted in Figure 4.
Discussion
The question of whether dose distribution and quality
are different in VMAT plans compared to IMRT plans
has been evaluated in a large number of studies [10-20].
Even if the results of these studies show some differences
that may be caused by different optimizing engines, the
number of arcs per plan, the linac type or tumor sites, the
conclusions are consistent: the plan quality does not
clearly differ between IMRT and VMAT. The main differ-
ence between the two techniques, and therefore an advan-
tage for VMAT, lies in the reduction in delivery time. This
study, in which Elekta VMAT plans generated with Eclipse
TPS from Varian are compared with IMRT, supports this
statement (IMRT: in average 99 seconds/field; VMAT: in
average 82 seconds/arc [26]). However, in contrast toases
1Am (n = 12) 2A (n = 12) 2Am (n = 12)
.2 (104.8 - 110.4)c+ 107.0 (103.6 - 112.8) 106.3 (103.6 - 109.0)a+c+
2.2 (83.5 - 99.2) 91.1 (75.6 - 99.8) 93.0 (81.0 - 99.8)
11 (1.05 - 1.18)c 1.13 (1.04 - 1.35) 1.10 (1.04 - 1.19)c
3 (0.67 - 0.93)ac 0.81 (0.56 - 0.94) 0.84 (0.65 - 0.94)ac
3.1 (4.4 - 20.7)c 13.2 (4.3 - 20.9) 13.2 (4.4 - 20.9)c
.3 (21.1 - 62.0)ac 45.4 (21.1 - 62.9)a+ 45.5 (21.0 - 62.4)a+c
.6 (51.3 - 56.7)ac 52.8 (51.0 - 55.1) 52.9 (51.0 - 55.1)c
.0 (1.5 - 31.2)a 5.7 (1.5 - 11.3) 6.9 (1.5 - 32.1)
.9 (1.5 - 11.7)a+ 5.5 (1.5 - 10.6)a 4.8 (1.5 - 11.6)a+
9.1 (1.5 - 31.2) 5.8 (1.5 - 11.3) 9.0 (1.5 - 32.1)
1.9 (36.5 - 60.7) 50.2 (29.8 - 60.3)b 51.4 (33.4 - 60.3)
1.0 (19.0 - 59.7) 39.8 (19.0 - 52.8)a 41.5 (19.7 - 60.0)
2.1 (31.4 - 47.8) 40.9 (29.2 - 46.6) 42.3 (30.0 - 49.6)
9.8 (19.0 - 59.7) 38.8 (19.0 - 52.8)a 40.8 (19.7 - 60.0)
02.6 (279–342)a 293.2 (156–331)a+ 293.7 (156–331)a+
he optimization penalties; values are expressed as the mean (range).
p < 0.05 1Am vs. 2Am; +p < 0.01.



























Figure 4 Mean DVHs of 12 brain cancer cases. Solid line: IMRT; thin dashed line: 1A; thin dotted line: 2A; fat dashed line: 1Am; fat dotted
line: 2Am.
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http://www.ro-journal.com/content/9/1/153other studies, the primary goal in this study was not to
generate “perfect” plans. With the introduced procedure
of the optimizing process, the influence of the operator
was eliminated or at least minimized. Therefore, the
proper quality of the optimizing engine is shown.
In summary, as shown in Table 2, it is possible to
create clinically acceptable and IMRT-comparable
plans based on templates using this VMAT optimizer
for all tumor regions. With the use of templates,
acceptable plans are easy to generate and minimal
operator experience or interaction is required. The
calculation times – often a disadvantage of VMAT
planning [9,10,13] – do not show large differences: the
time to optimize and calculate single-arc plans is
approximately 10 to 20% shorter than for IMRT; for
double arc plans, the time is 10 to 20% longer.
Regarding the individual tumor regions and dose
prescriptions, clear differences in the plan quality in
comparison to IMRT and between single- and double-
arc plans were identified. However, the values listed in
Tables 4, 5, 6 and 7 and in the Additional files 2, 3, 4
and 5 should be carefully interpreted based on the clin-
ical context. Even when statistical significance was
noted, the differences could be very small (e.g., V20 Gy
for total lung in breast cases: 10.3% for IMRT and 9.5%
for 2Am-VMAT, p: 0.027), or the differences were largebut the values were still within the tolerance range
(e.g., Dmax of brain stem for 69.3 Gy-HN cases: 35.3 Gy
for IMRT and 39.4 Gy for 2Am-VMAT, p: 0.014).
In the HN cases with SIB (64 Gy and 69.3 Gy), the
change in the percentage of plans with acceptable
target coverage before and after modification of the
optimization penalties was small (5%). However, the
OAR sparing was substantially improved (+21%). This
finding may indicate that the templates used were
not ideal, as confirmed by the analyses of the out-of-
tolerance parameters (mainly V28 Gy of the parotid
glands). However, the target coverage of the 69.3 Gy
plans was generally worse than in other tumor regions
and dose prescriptions. This finding indicates that in
complex cases with up to three different dose levels
(PTV1, PTV2, PTV3), the use of a generally valid tem-
plate cannot be expected to produce an ideal dose dis-
tribution without further individual adaptations.
Therefore, more effort is needed, particularly to achieve
an acceptable V95% value within the PTV1.
Plans with brain tumors showed similar behavior: the
acceptance rate was low (<50%). After modifying the
optimization penalties, no improvements could be iden-
tified for either the target volume or the OAR. In these
cases, small and fine structured contours such as lenses
and optical nerves often lie near to the target. During
Figure 5 Example of an endometrial plan showing the differences in target coverage and conformity. PTV in red and rectum in brown:
(a) IMRT: CN 0.73, V95% 96.1%, Dmax 109.7%; (b) 2A: CN 0.83, V95% 95.1%, Dmax 110.6%; (c) 1A: CN 0.78, V95% 92.2%, Dmax 112.4%.
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tion around the body, these OARs were effectively
always in the beam path. The MLCi of a leaf width of
1 cm without the possibility of interdigitation used in
this study limits the modulation to spare these small
structures. MLCs with smaller widths may improve the
plan quality for such cases [28-30]. IMRT also improves
plan quality; the fixed gantry angles can be placed sys-
tematically to avoid irradiation through certain regions
with such small structures.
The endometrial VMAT single-arc plans were remark-
able; here, only 21% of all plans were acceptable regard-
ing the PTV (in contrast to 68% for 2A). Similar to
some HN cases, the V95% values were statistically signifi-
cant lower than in the corresponding IMRT plans, and
the maximum dose was out of tolerance. The isodose
lines indicated that in the target region, many small hot
and cold spots were found (example in Figure 5). Again,
the limiting factor may be the 1 cm leaf width. However,
in contrast to the brain cases, a modulation with two
arcs allowed for the effect to be compensated.
Prostate plans including two hip implants must be
considered separately: the clinical parameters (Dmax and
V95% in the target, OAR sparing) for double-arc plans
were acceptable, mostly after modification of theFigure 6 Example of a prostate plan with two hip implants. The impla
in red; (a) IMRT: CN 0.81, rectum with V40 Gy 38.9%, V60 Gy 19.4%; bladder w
62.4%, V60 Gy 46.3%, bladder with V40 Gy 38.4%, V60 Gy 19.9%; (c) 2Am: CN 0
V60 Gy 21.1%.optimizing process. Before the modification, the sparing
of the OAR (especially V40 Gy and V60 Gy of the rectum
and V60 Gy and V70 Gy of the bladder) was out of toler-
ance and could be improved to passing rates of 81% for
2A plans and 63% for 1A plans. However, the conformity
– for which no tolerance limit was given – lay statisti-
cally significant below the value of the IMRT plans be-
fore and after the modification (CN: 0.81 (IMRT), CN:
0.74 (VMAT), p: 0.03). The isodose lines of these plans
clearly indicated that the dose-volume objectives were
met with the values given in Table 1, but healthy tissue
around the target was irradiated at a non-acceptable
level (example in Figure 6).
As summarized in Tables 2 and 3 and shown in the
detailed results for each tumor region, plans with two
arcs provided a better plan quality than plans with one
arc. The differences varied but were mainly significant
and clinically important for the target coverage, particu-
larly for the following: breast (Dmax: 114.1% [1A] vs.
109.4% [2A], V95%: 85.6% [1A] vs. 89.9% [2A]), prostate
with one hip implant (V95%: 94.8% [1A] vs. 96.4% [2A])
and cervical plans (Dmax: 111.3% [1A] vs. 109.4% [2A],
V95%: 91.9% vs. 95.2% [2A]). Clinically acceptable target
dose coverage was difficult to achieve with a single-arc
technique; however, it was possible with two arcs.nts are in yellow (left) and light blue (right), the rectum in brown, PTV
ith V40 Gy 31.1%, V60 Gy 18.0%; (b) 2A: CN 0.79, rectum with V40 Gy
.74, rectum with V40 Gy 60.6%, V60 Gy 33.8%, bladder with V40 Gy 39.7%,
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plans. However, the differences were often small and de-
tectable even when statistically significant with no clinical
relevance, e.g., Dmax of the bladder for cervical cases:
47.8 Gy (1A) vs. 47.3 Gy (2A); Dmax of the brainstem of
64 Gy-HN-cases: 41.8 Gy (1A) vs. 39.4 Gy (2A) and V20 Gy
of the lungs for breast cases: 10.0% (1A) vs. 9.5% (2A).
The integral body dose and the number of MUs were
significantly different in favor of VMAT; the number of
MUs was approximately 30% smaller compared to IMRT
(except for prostate with hip implants, where the num-
ber of MUs was approximately the same). This value is
comparable to previous studies on step-and-shoot IMRT
that reported reductions of 12% to 20% [10,31] and stud-
ies on sliding-window IMRT that reported reductions
of 40% to 55% [11,16]. As the number of MUs per treat-
ment is correlated with the amount of scatter dose and
leakage radiation, which could be important based on
the induction of secondary malignancies [32,33], a de-
crease in the number of MUs achieved with VMAT is
desirable. Furthermore, the evaluated plans had highly
significant lower total integral doses (p < 0.001), which
was represented by the mean dose to the patient body
(VMAT: 15.3 Gy; IMRT 16.0 Gy). But the differences
depend strongly on the tumor region: the smallest differ-
ences of 0.1 Gy were identified for HN cases with 64 Gy,
and the largest differences (0.9 Gy) were identified for
endometrial cases. These values are not consistent with
the findings of some previous studies [10,20,34,35] that
reported that the integral dose delivered to the patient is
independent of the number of beams and the treatment
technique; however, some other studies confirm our re-
sults [11,16,18]. In contrast, the total body volume re-
ceiving at least 5 Gy (V5Gy) was slightly larger for
VMAT (+0.7% with p < 0.001) than for IMRT. This find-
ing indicates that the integral dose for VMAT was
smaller and mainly visible in the high-dose region; how-
ever, the low-dose region was slightly larger than for
IMRT, possibly because the dose is spread all over the
body, in contrast to IMRT, in which high doses are
achieved only in the beam directions and hardly any
doses are achieved outside of the beam directions.
Conclusions
The results of this study have demonstrated that the
quality achieved using the Varian Eclipse treatment plan-
ning system with single- and double-arc VMAT plans
for Elekta linear accelerators is comparable to that of
fixed-field step-and-shoot IMRT for a variety of tumor
sites. Furthermore, plans with two arcs provide better
dose distributions than plans with one arc. In addition,
the template-based planning approach demonstrates that
with minimal effort, clinically acceptable plans can be
generated. Additionally, the reduced treatment time andsmaller number of MUs are the major advantages of
VMAT compared with IMRT. These results show that
VMAT using Eclipse as TPS for Elekta linear accelera-
tors is a valuable alternative to well-established IMRT
technique in clinical routine.
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